Literature DB >> 11927129

Four missense mutations identified in the protein S gene of thrombosis patients with protein S deficiency: effects on secretion and anticoagulant activity of protein S.

Hiroko Tsuda1, Michiyo Urata, Tomohide Tsuda, Machiko Wakiyama, Hiroko Iida, Mutsuko Nakahara, Sachiko Kinoshita, Naotaka Hamasaki.   

Abstract

Four missense mutations, G54R, T589I, K155E, and Y595C, were identified in the protein S (PS) gene of the patients with PS deficiency and venous thrombosis. Three patients were heterozygous for the novel mutations, G54R, T589I, and Y595C, while a remaining one patient was homozygous for the K155E mutation, which is known to be a polymorphism in the Japanese population. A family study revealed that the Y595C mutation was associated with a Type I PS deficiency and the K155E mutation with a Type II PS deficiency, while no family study was performed for the patients with the G54R and T589I mutations. To determine whether these four mutations play a causative role in PS deficiency, the four PS mutants and wild-type PS were stably expressed in human embryo kidney (HEK) 293 cells. Pulse-chase experiments showed intracellular degradation and decreased secretion of the Y595C mutant. In the activated protein C (APC) cofactor assays, the specific activity of the K155E mutant decreased to 58% of that of wild-type PS. The APC cofactor activity of the three mutants, G54R, K155E, and T589I, were inhibited by C4b-binding protein (C4BP) with a dose dependency similar to that of wild-type PS. These results indicate that the Y595C and the K155E mutations are responsible for a secretion defect and a decreased anticoagulant activity of PS, respectively. The remaining two mutations, G54R and T589I, however, did not produce any definite abnormality leading to a low plasma PS activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927129     DOI: 10.1016/s0049-3848(02)00015-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Compound heterozygous mutations in the PROS1 gene responsible for quantitative and qualitative protein S deficiency.

Authors:  Jun Yamanouchi; Takaaki Hato; Tatsushiro Tamura; Hiroshi Fujiwara; Yoshihiro Yakushijin; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2009-10-14       Impact factor: 2.490

2.  High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism.

Authors:  Makoto Ikejiri; Hideo Wada; Norikazu Yamada; Maki Nakamura; Naoki Fujimoto; Kaname Nakatani; Akimasa Matsuda; Yosihito Ogihara; Takeshi Matsumoto; Yuki Kamimoto; Tomoaki Ikeda; Naoyuki Katayama; Masaaki Ito
Journal:  Int J Hematol       Date:  2016-10-20       Impact factor: 2.490

3.  Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain.

Authors:  Helena M Andersson; Márcia J Arantes; James T B Crawley; Brenda M Luken; Sinh Tran; Björn Dahlbäck; David A Lane; Suely M Rezende
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

4.  Carrier frequencies of antithrombin, protein C, and protein S deficiency variants estimated using a public database and expression experiments.

Authors:  Keiko Maruyama; Koichi Kokame
Journal:  Res Pract Thromb Haemost       Date:  2020-11-27

Review 5.  Activated protein C anticoagulant system dysfunction and thrombophilia in Asia.

Authors:  Naotaka Hamasaki; Hiroyuki Kuma; Hiroko Tsuda
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464

6.  Protein S K196E mutation reduces its cofactor activity for APC but not for TFPI.

Authors:  Keiko Maruyama; Masashi Akiyama; Toshiyuki Miyata; Koichi Kokame
Journal:  Res Pract Thromb Haemost       Date:  2018-09-25

7.  Childhood Nephrotic Syndrome Complicated by Catastrophic Multiple Arterial Thrombosis Requiring Bilateral Above-Knee Amputation.

Authors:  Hayato Togashi; Yuko Shimosato; Ken Saida; Noriko Miyake; Takeshi Nakamura; Shuichi Ito
Journal:  Front Pediatr       Date:  2020-03-19       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.